Srinivas Tantravahi, MD
Hematology · Salt Lake City, UTNPI 1972742245
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $65,385 of the $80,709 with a category attached, or 81.0%. 15 manufacturers reported payments, led by Karyopharm Therapeutics Inc. at 36.4% of the total. Reporting peaked in 2023 at $28,966 and has fallen 74.9% since, to $7,265 in 2025.
Across 81 payments — averaging $996.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$29K
- Novartis$15K
- GSK$10K
- CTI Biopharma Corp.$8K
- Genentech, Inc.$7K
- Incyte Corporation$5K
- plus $7K from 9 others
Across 2,344 payments — averaging $6743.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$12.4M
- Karyopharm Therapeutics Inc.$1.6M
- Incyte Corporation$703K
- AbbVie$560K
- Sumitomo Pharma America, Inc.$332K
- E.r. Squibb & Sons, L.L.C.$167K
- plus $54K from 4 others
What the payments were for
- Consulting fees$65,38581%
- Speaking & faculty fees$8,91311%
- Travel & lodging$3,5384%
- Food & beverage$2,8314%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 25 | $29,373 |
| Novartis | 15 | $15,068 |
| GSK | 12 | $10,148 |
| CTI Biopharma Corp. | 1 | $7,500 |
| Genentech, Inc. | 5 | $6,675 |
| Incyte Corporation | 7 | $5,206 |
| AbbVie | 4 | $2,200 |
| Morphosys, US Inc. | 3 | $2,079 |
| Bristol Myers Squibb | 2 | $1,998 |
| Sanofi | 2 | $131 |
| Janssen Scientific Affairs, LLC | 1 | $110 |
| Apellis Pharmaceuticals, Inc. | 1 | $90 |
| Sumitomo Pharma America, Inc. | 1 | $50 |
| AstraZeneca | 1 | $43 |
| Stemline Therapeutics Inc. | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ScemblixAsciminib Hydrochloride | 44 | $1,602,982 |
| JakafiRuxolitinib Phosphate | 78 | $1,264,115 |
| IclusigPonatinib Hcl | 36 | $767,035 |
| SprycelDasatinib | 58 | $631,586 |
| OjjaaraMomelotinib Dihydrochloride | 18 | $493,028 |
| BosulifBosutinib | 30 | $325,870 |
| RevlimidLenalidomide | 14 | $247,817 |
| Dasatinib | 11 | $86,180 |
| VenclextaVenetoclax | 24 | $44,358 |
| Posaconazole | 19 | $17,445 |
| EliquisApixaban | 12 | $7,200 |
| Cyclosporine ModifiedCyclosporine, Modified | 28 | $3,213 |
| Danazol | 12 | $2,655 |
| Deferasirox | 11 | $2,622 |
| Imatinib Mesylate | 28 | $2,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisScemblix | $15,068 | $1,602,98244 claims |
| Incyte CorporationJakafi | $5,206 | $1,264,11578 claims |
| GSKOjjaara | $10,148 | $493,02818 claims |
| Bristol Myers SquibbRevlimid | $1,998 | $247,81714 claims |
| AbbVieVenclexta, Gengraf | $2,200 | $45,50242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Utahon file to place this against a meaningful peer group, so we don't.
Other hematology in Salt Lake City
- George RodgersSalt Lake City$133K
- Deborah StephensSalt Lake City$98K
- Daniel ErmannSalt Lake City$74K
- Charles ParkerSalt Lake City$54K
- Jay PatelSalt Lake City$49K
- Josef PrchalSalt Lake City$48K
- Ami PatelSalt Lake City$5K
- Kristi SmockSalt Lake City$4K
- Margaret BaronSalt Lake City$524
- Archana AgarwalSalt Lake City$345
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.